Want to see IN:PANACEABIO full AI Analyst Report?
Panacea Biotec Limited (PANACEABIO) Ratios
Panacea Biotec Limited Ratios
IN:PANACEABIO's free cash flow for Q1 2027 was $0.00. For the 2027 fiscal year, IN:PANACEABIO's free cash flow was increased by $0.00 and operating cash flow was $0.00. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.47 | 1.49 | 1.57 | 1.71 | 1.28 |
| Quick Ratio | 0.92 | 0.90 | 0.99 | 1.10 | 1.00 |
| Cash Ratio | 0.18 | 0.22 | 0.15 | 0.12 | 0.06 |
| Solvency Ratio | 0.06 | 0.06 | 0.09 | 0.01 | 1.27 |
| Operating Cash Flow Ratio | 0.05 | -0.07 | -0.00 | -1.27 | -0.14 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | -7680.95 | -2085.54 |
| Net Current Asset Value | $ 797.50M | $ 860.50M | $ 827.31M | $ 1.37B | $ 1.05B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Debt-to-Equity Ratio | 0.03 | 0.03 | 0.02 | 0.02 | 0.04 |
| Debt-to-Capital Ratio | 0.03 | 0.03 | 0.02 | 0.02 | 0.04 |
| Long-Term Debt-to-Capital Ratio | 0.03 | 0.03 | 0.02 | 0.02 | 0.04 |
| Financial Leverage Ratio | 1.51 | 1.54 | 1.47 | 1.51 | 2.01 |
| Debt Service Coverage Ratio | -0.74 | 7.72 | 10.77 | 2.18 | 7.20 |
| Interest Coverage Ratio | -6.23 | -15.65 | -3.86 | -23.81 | -0.29 |
| Debt to Market Cap | 0.01 | 0.01 | 0.03 | 0.03 | 0.04 |
| Interest Debt Per Share | 4.87 | 4.27 | 3.99 | 4.03 | 35.10 |
| Net Debt to EBITDA | 8.74 | -1.95 | -0.63 | -0.35 | -0.01 |
| Profitability Margins | |||||
| Gross Profit Margin | 22.73% | 64.31% | 8.09% | 38.99% | 51.81% |
| EBIT Margin | -5.90% | -0.73% | 0.92% | 3.77% | 247.14% |
| EBITDA Margin | -0.73% | 5.50% | 7.53% | 12.34% | 253.93% |
| Operating Profit Margin | -5.90% | -10.86% | -2.50% | -23.12% | -7.86% |
| Pretax Profit Margin | -1.15% | -1.42% | 0.27% | 2.80% | 219.86% |
| Net Profit Margin | -0.84% | -1.50% | -0.21% | -7.27% | 163.57% |
| Continuous Operations Profit Margin | -1.12% | -1.56% | -0.27% | -7.39% | 163.58% |
| Net Income Per EBT | 72.86% | 105.28% | -79.42% | -259.56% | 74.40% |
| EBT Per EBIT | 19.54% | 13.09% | -10.70% | -12.12% | -2797.17% |
| Return on Assets (ROA) | -0.43% | -0.65% | -0.09% | -2.61% | 61.31% |
| Return on Equity (ROE) | -0.64% | -1.00% | -0.14% | -3.94% | 123.01% |
| Return on Capital Employed (ROCE) | -4.13% | -6.58% | -1.48% | -11.25% | -5.27% |
| Return on Invested Capital (ROIC) | -4.01% | -6.58% | 1.51% | 29.64% | -3.92% |
| Return on Tangible Assets | -0.44% | -0.67% | -0.10% | -2.67% | 61.79% |
| Earnings Yield | -0.30% | -0.30% | -0.14% | -5.00% | 118.79% |
| Efficiency Ratios | |||||
| Receivables Turnover | 8.48 | 7.44 | 8.95 | 7.27 | 7.83 |
| Payables Turnover | 2.61 | 0.88 | 1.75 | 1.57 | 1.35 |
| Inventory Turnover | 2.56 | 0.93 | 1.51 | 1.38 | 1.49 |
| Fixed Asset Turnover | 0.98 | 0.88 | 0.87 | 0.73 | 1.05 |
| Asset Turnover | 0.51 | 0.43 | 0.44 | 0.36 | 0.37 |
| Working Capital Turnover Ratio | 3.74 | 3.15 | 2.67 | 2.03 | 4.78 |
| Cash Conversion Cycle | 45.41 | 26.93 | 73.69 | 82.66 | 21.32 |
| Days of Sales Outstanding | 43.05 | 49.05 | 40.78 | 50.23 | 46.59 |
| Days of Inventory Outstanding | 142.35 | 390.85 | 241.48 | 264.62 | 244.42 |
| Days of Payables Outstanding | 140.00 | 412.96 | 208.57 | 232.18 | 269.70 |
| Operating Cycle | 185.41 | 439.90 | 282.25 | 314.84 | 291.01 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 2.84 | -4.48 | -0.02 | -68.97 | -17.71 |
| Free Cash Flow Per Share | -6.02 | -12.71 | -12.64 | -75.66 | -19.75 |
| Dividend Paid and CapEx Coverage Ratio | 0.32 | -0.54 | -0.00 | -10.32 | -8.67 |
| Capital Expenditure Coverage Ratio | 0.32 | -0.54 | -0.00 | -10.32 | -8.67 |
| Operating Cash Flow Coverage Ratio | 0.73 | -1.23 | -0.00 | -20.89 | -3.18 |
| Operating Cash Flow to Sales Ratio | 0.03 | -0.05 | -0.00 | -0.92 | -0.16 |
| Free Cash Flow Yield | -2.03% | -2.81% | -9.56% | -69.76% | -13.33% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -336.42 | -330.04 | -694.27 | -19.99 | 0.84 |
| Price-to-Sales (P/S) Ratio | 2.82 | 4.94 | 1.48 | 1.45 | 1.38 |
| Price-to-Book (P/B) Ratio | 2.16 | 3.31 | 0.97 | 0.79 | 1.04 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -49.16 | -35.56 | -10.47 | -1.43 | -7.50 |
| Price-to-Operating Cash Flow Ratio | 104.19 | -100.93 | -8143.82 | -1.57 | -8.37 |
| Price-to-Earnings Growth (PEG) Ratio | 9.41 | -0.53 | 7.19 | 0.19 | -0.00 |
| Enterprise Value Multiple | -378.94 | 87.91 | 18.98 | 11.44 | 0.53 |
| Enterprise Value | 17.66B | 27.02B | 7.88B | 6.45B | 8.92B |
| EV to EBITDA | -378.94 | 87.91 | 18.98 | 11.44 | 0.53 |
| EV to Sales | 2.76 | 4.83 | 1.43 | 1.41 | 1.35 |
| EV to Free Cash Flow | -48.05 | -34.79 | -10.13 | -1.39 | -7.37 |
| EV to Operating Cash Flow | 101.84 | -98.74 | -7881.98 | -1.53 | -8.22 |
| Tangible Book Value Per Share | 127.49 | 129.04 | 130.28 | 132.92 | 140.38 |
| Shareholders’ Equity Per Share | 136.81 | 136.64 | 136.74 | 137.73 | 143.12 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.03 | -0.10 | 2.02 | 3.64 | 0.26 |
| Revenue Per Share | 104.84 | 91.51 | 89.63 | 74.60 | 107.63 |
| Net Income Per Share | -0.88 | -1.37 | -0.19 | -5.43 | 176.05 |
| Tax Burden | 0.73 | 1.05 | -0.79 | -2.60 | 0.74 |
| Interest Burden | 0.20 | 1.95 | 0.29 | 0.74 | 0.89 |
| Research & Development to Revenue | 0.00 | 0.08 | 0.07 | 0.07 | 0.02 |
| SG&A to Revenue | 0.29 | 0.38 | 0.05 | 0.03 | 0.04 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | -3.23 | 3.44 | 0.09 | -33.00 | -0.07 |
Currency in INR